Beata Krasuska-Grzegorczyk, Łukasz Komsta, Z. Danilczuk
Considerable evidence suggests that glucocorticoids (GCs) play an important role in neurodegeneration. Chronic elevated levels of GCs can result in neuronal degeneration of the hippocampal piramidal neurons, which are paralleled by cognitive deficits. Moreover, GCs potentiate stress or ischemia-induced accumulation of excitatory amino acids (EAA) in the extracellular space of hippocampus. ACEA 1021 (licostinel), a selective antagonist of the N-methyl-D-aspartate (NMDA) receptor, has been reported to prevent the excitotoxic action of high extracellular glutamate levels. The aim of this study was to investigate the effect of ACEA 1021 on neurotoxic effect of dexamethasone (DEX - a synthetic GCs receptor agonist). The experiments were carried out on Albino Swiss mice (25-30 g). ACEA 1021, at the doses: 1.25 and 2.5 mg/kg/day, ip, was administered 15 min before DEX (16 mg/kg/day, ip). The long-term memory acquisition (passive avoidance test) and the motor performance (“chimney” test) were evaluated 14 days after the drugs administration. The prolongation of climbing time in the “chimney” test and decrease of the retention time in the memory task of mice treated with DEX for 14 days. In mice treated with DEX for 14 days, ACEA 1021 at the both doses reduced the climbing time in the “chimney” test, at the dose of 1.25 mg/kg improved memory acquisition. The above findings suggest that ACEA 1021 could prevent the neurotoxic effects induced by DEX, but further study needs to be carried out to explain this effect.
{"title":"Effect of ACEA 1021 on Neurotoxicity Induced by Dexamethasone — Initial Behavioral Study","authors":"Beata Krasuska-Grzegorczyk, Łukasz Komsta, Z. Danilczuk","doi":"10.32383/appdr/185546","DOIUrl":"https://doi.org/10.32383/appdr/185546","url":null,"abstract":"Considerable evidence suggests that glucocorticoids (GCs) play an important role in neurodegeneration. Chronic elevated levels of GCs can result in neuronal degeneration of the hippocampal piramidal neurons, which are paralleled by cognitive deficits. Moreover, GCs potentiate stress or ischemia-induced accumulation of excitatory amino acids (EAA) in the extracellular space of hippocampus. ACEA 1021 (licostinel), a selective antagonist of the N-methyl-D-aspartate (NMDA) receptor, has been reported to prevent the excitotoxic action of high extracellular glutamate levels. The aim of this study was to investigate the effect of ACEA 1021 on neurotoxic effect of dexamethasone (DEX - a synthetic GCs receptor agonist). The experiments were carried out on Albino Swiss mice (25-30 g). ACEA 1021, at the doses: 1.25 and 2.5 mg/kg/day, ip, was administered 15 min before DEX (16 mg/kg/day, ip). The long-term memory acquisition (passive avoidance test) and the motor performance (“chimney” test) were evaluated 14 days after the drugs administration. The prolongation of climbing time in the “chimney” test and decrease of the retention time in the memory task of mice treated with DEX for 14 days. In mice treated with DEX for 14 days, ACEA 1021 at the both doses reduced the climbing time in the “chimney” test, at the dose of 1.25 mg/kg improved memory acquisition. The above findings suggest that ACEA 1021 could prevent the neurotoxic effects induced by DEX, but further study needs to be carried out to explain this effect.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"23 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140724615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Wylegała, Marcin Czech, Urszula Religioni, Dariusz Stencel
All tasks performed by hospital pharmacies concern the management of medicinal products. The aim of this work is to analyze the functioning and implemen-tation costs of unit-dose and multi-dose automatic drug distribution systems in comparison with the classical mode of so-called ward medicine cabinets. The study was conducted from January 2020 to October 2021. It included quantitative study, conducted to verify the functioning of hospital phar-macies based on an original questionnaire, which was completed by 26 masters of pharmacy em-ployed in pharmacies hospitals, of which 92.4% were pharmacy head, and in-depth face-to-face interviews conducted in 4 facilities with unit-dose systems and one center that uses the multi-dose system. The work presents the functioning of hospital pharmacies, and the advantages and disadvantages of classical distri-bution model. Opinions on the operation of unit-dose and multi-dose systems as well as experiences related to their implementation in the hospital, including the necessary changes in the structure and organization of the hospital, were also presented. In conclusion, despite high purchase costs, auto-mated drug distribution systems bring many benefits in the field of hospital functioning, mainly in relation to patient care, improving the effectiveness, safety and individualization of pharmacothera-py. The main barriers to implementation of these systems are high costs, lack of IT infrastructure adaptation, the need to change the organization of staff work and the lack of factory-prepared col-lective packaging. In the opinion of pharmacists, changes in the distribution of drugs are necessary and beneficial from proper pharmacotherapy perspective.
{"title":"Are Polish Hospital Pharmacies Ready for Changes in Drug Distribution?","authors":"K. Wylegała, Marcin Czech, Urszula Religioni, Dariusz Stencel","doi":"10.32383/appdr/185879","DOIUrl":"https://doi.org/10.32383/appdr/185879","url":null,"abstract":"All tasks performed by hospital pharmacies concern the management of medicinal products. The aim of this work is to analyze the functioning and implemen-tation costs of unit-dose and multi-dose automatic drug distribution systems in comparison with the classical mode of so-called ward medicine cabinets. The study was conducted from January 2020 to October 2021. It included quantitative study, conducted to verify the functioning of hospital phar-macies based on an original questionnaire, which was completed by 26 masters of pharmacy em-ployed in pharmacies hospitals, of which 92.4% were pharmacy head, and in-depth face-to-face interviews conducted in 4 facilities with unit-dose systems and one center that uses the multi-dose system. The work presents the functioning of hospital pharmacies, and the advantages and disadvantages of classical distri-bution model. Opinions on the operation of unit-dose and multi-dose systems as well as experiences related to their implementation in the hospital, including the necessary changes in the structure and organization of the hospital, were also presented. In conclusion, despite high purchase costs, auto-mated drug distribution systems bring many benefits in the field of hospital functioning, mainly in relation to patient care, improving the effectiveness, safety and individualization of pharmacothera-py. The main barriers to implementation of these systems are high costs, lack of IT infrastructure adaptation, the need to change the organization of staff work and the lack of factory-prepared col-lective packaging. In the opinion of pharmacists, changes in the distribution of drugs are necessary and beneficial from proper pharmacotherapy perspective.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"11 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140722899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aleksandar Rančić, M. Folic, Nemanja Petrović, Violeta Ilić Todorović, Milica Stanojević, Miloš N. Milosavljević, Milica Milentijević, Slobodan M Janković
Eminent societies of clinicians worldwide advise the implementation of therapeutic monitoring of meropenem. Our aim was to validate the new high-performance liquid chromatography (HPLC) technique for the measurement of meropenem in plasma that we developed. The validation of the method was performed in accordance with the official European Medicines Agency (EMA) guideline for bioanalytical method validation through the assessment of the following validation parameters: linearity and limit of detection/quantification, trueness and precision, recovery, selectivity, matrix-effect assessment, dilution integrity, carry-over assessment, and stability. Our calibration curve was found to be linear over the concentration ranges of 1.25–100 μg/mL, which covers the therapeutic range of meropenem in patients. From the calibration curve, the limits of detection and quantification were calculated to be 0.4 μg/mL and 1.2 μg/mL, respectively. Recovery ranged from 81.7 to 95.9 percent. Intra-day truennes ranged from −1.9 to 2.6% and inter-day trueness ranged from −4.7 to 3.8%. Intra-day precision was less than 4 percent, while inter-day precision was less than 7 percent. Meropenem remained stable in the patient plasma sample for one week at −20°C. Our HPLC technique can be applied in clinical practice for the therapeutic monitoring of meropenem in critically ill and other vulnerable patients since it is simple, rapid, and reliable.
{"title":"Validation of Novel High-Performance Liquid Chromatography Method for Meropenem Quantification in Plasma","authors":"Aleksandar Rančić, M. Folic, Nemanja Petrović, Violeta Ilić Todorović, Milica Stanojević, Miloš N. Milosavljević, Milica Milentijević, Slobodan M Janković","doi":"10.32383/appdr/183621","DOIUrl":"https://doi.org/10.32383/appdr/183621","url":null,"abstract":"Eminent societies of clinicians worldwide advise the implementation of therapeutic monitoring of meropenem. Our aim was to validate the new high-performance liquid chromatography (HPLC) technique for the measurement of meropenem in plasma that we developed. The validation of the method was performed in accordance with the official European Medicines Agency (EMA) guideline for bioanalytical method validation through the assessment of the following validation parameters: linearity and limit of detection/quantification, trueness and precision, recovery, selectivity, matrix-effect assessment, dilution integrity, carry-over assessment, and stability. Our calibration curve was found to be linear over the concentration ranges of 1.25–100 μg/mL, which covers the therapeutic range of meropenem in patients. From the calibration curve, the limits of detection and quantification were calculated to be 0.4 μg/mL and 1.2 μg/mL, respectively. Recovery ranged from 81.7 to 95.9 percent. Intra-day truennes ranged from −1.9 to 2.6% and inter-day trueness ranged from −4.7 to 3.8%. Intra-day precision was less than 4 percent, while inter-day precision was less than 7 percent. Meropenem remained stable in the patient plasma sample for one week at −20°C. Our HPLC technique can be applied in clinical practice for the therapeutic monitoring of meropenem in critically ill and other vulnerable patients since it is simple, rapid, and reliable.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"33 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140721424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Agnieszka Gierczak-Pachulska, M. Kaza, Katarzyna Jarus-Dziedzic, Olga Czerepow-Bielik, A. Segiet-Święcicka, Grzegorz Huszcza, Katarzyna Sidoruk, Daniel Rabczenko, P. Rudzki
Rivaroxaban is an oral anticoagulant that is a selective, direct factor Xa inhibitor. It is used to prevent thrombotic events of atherosclerotic etiology and to prevent stroke and peripheral embolism in adult patients with nonvalvular atrial fibrillation. The aim of studies was to assess the bioequivalence of two orally administered products: test (Zarixa hard capsules) vs. reference (Xarelto® film-coated tablets). Two crossover, 2-period, randomized, open-label, laboratory-blinded studies were conducted in healthy White male and female volunteers. A single oral dose (Study 1: 10 mg fasting, Study 2: 20 mg fed) of the test or reference product was followed by a minimum 7-day washout. Blood was collected up to 48 h after administration. Plasma concentrations of rivaroxaban were measured using a validated LC-MS/MS method. The bioequivalence criteria for 90% confidence intervals (CI) of the log-transformed geometric mean ratios (test/reference) for the two primary pharmacokinetic parameters (AUC(0-t) and Cmax) were set at 80.00-125.00%. Vital signs, laboratory parameters, and adverse events were monitored. 34 of 36 volunteers completed Study 1, and geometric mean ratios were 97.96% (90% CI 93.69-102.42%) for AUC(0-t), and 89.35% (90% CI 84.28-94.72%) for Cmax. All 36 volunteers completed Study 2, and geometric mean ratios were 103.57% (90% CI 98.75-108.63%) for AUC(0-t), and 95.17% (90% CI 87.35-103.70%) for Cmax. All of 90% CIs for the primary pharmacokinetic parameter ratios met acceptance criteria. There were no serious adverse events. Results of both studies indicate that the test product (Zarixa) is bioequivalent to the reference product (Xarelto®). Both products were well tolerated.
利伐沙班是一种口服抗凝剂，是一种选择性直接 Xa 因子抑制剂。它用于预防动脉粥样硬化引起的血栓事件，以及预防非瓣膜性心房颤动成年患者的中风和外周栓塞。研究旨在评估两种口服产品的生物等效性：试验产品（扎瑞沙硬胶囊）与参照产品（Xarelto® 膜衣片）。在健康的白人男性和女性志愿者中进行了两项交叉、两期、随机、开放标签、实验室盲法研究。试验或参比产品的单次口服剂量（研究 1：空腹 10 毫克；研究 2：进食 20 毫克）后至少要进行 7 天的冲洗。给药后 48 小时内采集血液。采用经过验证的 LC-MS/MS 方法测量利伐沙班的血浆浓度。两个主要药代动力学参数（AUC(0-t) 和 Cmax）的对数变换几何平均比值（试验/参照）的 90% 置信区间 (CI) 的生物等效性标准定为 80.00-125.00%。对生命体征、实验室参数和不良事件进行了监测。36 名志愿者中有 34 人完成了研究 1，AUC(0-t)的几何平均比为 97.96%（90% CI 93.69-102.42%），Cmax 的几何平均比为 89.35%（90% CI 84.28-94.72%）。所有 36 名志愿者都完成了研究 2，AUC（0-t）的几何平均比为 103.57%（90% CI 98.75-108.63%），Cmax 为 95.17%（90% CI 87.35-103.70%）。所有主要药代动力学参数比值的 90% CI 均符合接受标准。没有发生严重不良事件。两项研究结果表明，试验产品（Zarixa）与参比产品（Xarelto®）具有生物等效性。两种产品的耐受性均良好。
{"title":"Bioequivalence of Rivaroxaban Hard Capsules vs. Film-Coated Tablets in Healthy White Volunteers","authors":"Agnieszka Gierczak-Pachulska, M. Kaza, Katarzyna Jarus-Dziedzic, Olga Czerepow-Bielik, A. Segiet-Święcicka, Grzegorz Huszcza, Katarzyna Sidoruk, Daniel Rabczenko, P. Rudzki","doi":"10.32383/appdr/185676","DOIUrl":"https://doi.org/10.32383/appdr/185676","url":null,"abstract":"Rivaroxaban is an oral anticoagulant that is a selective, direct factor Xa inhibitor. It is used to prevent thrombotic events of atherosclerotic etiology and to prevent stroke and peripheral embolism in adult patients with nonvalvular atrial fibrillation. The aim of studies was to assess the bioequivalence of two orally administered products: test (Zarixa hard capsules) vs. reference (Xarelto® film-coated tablets). Two crossover, 2-period, randomized, open-label, laboratory-blinded studies were conducted in healthy White male and female volunteers. A single oral dose (Study 1: 10 mg fasting, Study 2: 20 mg fed) of the test or reference product was followed by a minimum 7-day washout. Blood was collected up to 48 h after administration. Plasma concentrations of rivaroxaban were measured using a validated LC-MS/MS method. The bioequivalence criteria for 90% confidence intervals (CI) of the log-transformed geometric mean ratios (test/reference) for the two primary pharmacokinetic parameters (AUC(0-t) and Cmax) were set at 80.00-125.00%. Vital signs, laboratory parameters, and adverse events were monitored. 34 of 36 volunteers completed Study 1, and geometric mean ratios were 97.96% (90% CI 93.69-102.42%) for AUC(0-t), and 89.35% (90% CI 84.28-94.72%) for Cmax. All 36 volunteers completed Study 2, and geometric mean ratios were 103.57% (90% CI 98.75-108.63%) for AUC(0-t), and 95.17% (90% CI 87.35-103.70%) for Cmax. All of 90% CIs for the primary pharmacokinetic parameter ratios met acceptance criteria. There were no serious adverse events. Results of both studies indicate that the test product (Zarixa) is bioequivalent to the reference product (Xarelto®). Both products were well tolerated.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"48 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140724058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mariam Nersezashvili, K. Skalicka‐Woźniak, Dali Berashvili
The Apiaceae family, formerly known as Umbelliferae, is one of the largest plant families, composed of 466 genera and nearly 3800 species worldwide. According to the Royal Kew Garden, it is also one of 12 plant families with a higher than-normal percentage of medicinal species, ranking 6th with 15% of its plants counted as medicinal. Seseli species, known for their high coumarin content as well as terpenoids, flavonoids, essential oils, and more, have been extensively investigated and found to possess various pharmacological properties such as antimicrobial, antitumor, antioxidant, cytotoxic, anti-nociceptive, anti-inflammatory, etc. Some Seseli species have also been used in treating central nervous system disorders such as anxiety. From 135 species 12 are distributed in Georgia (original name of the country is Sakhartvelo), from which 3 are endemics. Despite numerous studies on the chemical composition and pharmacological properties of various Seseli species, some remain unexplored, especially those found in Georgia, where data is limited and out of date. Therefore, further extensive research is necessary to improve understanding of the pharmacological activities, chemical constituents, and efficacy of plants from the Georgian Seseli species. The presented review draws attention to Seseli species distributed in Georgia, their phytochemistry, botanical characterisation and traditional use. However, as the information on biological activity of Georgian Seseli spp. is limited, we discussed potential pharmacological properties expected based on their chemical composition, also in relation with the same species from other countries or botanical gardens.
{"title":"Phytochemical and Pharmaceutical Characterization of Seseli L. Species From Georgia","authors":"Mariam Nersezashvili, K. Skalicka‐Woźniak, Dali Berashvili","doi":"10.32383/appdr/185727","DOIUrl":"https://doi.org/10.32383/appdr/185727","url":null,"abstract":"The Apiaceae family, formerly known as Umbelliferae, is one of the largest plant families, composed of 466 genera and nearly 3800 species worldwide. According to the Royal Kew Garden, it is also one of 12 plant families with a higher than-normal percentage of medicinal species, ranking 6th with 15% of its plants counted as medicinal. Seseli species, known for their high coumarin content as well as terpenoids, flavonoids, essential oils, and more, have been extensively investigated and found to possess various pharmacological properties such as antimicrobial, antitumor, antioxidant, cytotoxic, anti-nociceptive, anti-inflammatory, etc. Some Seseli species have also been used in treating central nervous system disorders such as anxiety. From 135 species 12 are distributed in Georgia (original name of the country is Sakhartvelo), from which 3 are endemics. Despite numerous studies on the chemical composition and pharmacological properties of various Seseli species, some remain unexplored, especially those found in Georgia, where data is limited and out of date. Therefore, further extensive research is necessary to improve understanding of the pharmacological activities, chemical constituents, and efficacy of plants from the Georgian Seseli species. The presented review draws attention to Seseli species distributed in Georgia, their phytochemistry, botanical characterisation and traditional use. However, as the information on biological activity of Georgian Seseli spp. is limited, we discussed potential pharmacological properties expected based on their chemical composition, also in relation with the same species from other countries or botanical gardens.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"52 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140723746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Protein kinase CK2 has become a target of experimental antiglioma therapies as laboratory data are almost uniformly favorable and the number of synthetized CK2 inhibitors is rapidly growing. The evidence of their use for other brain tumors is on the increase as well. Great expectations are entrusted in naturally occurring compounds capable of inhibiting CK2 kinase. These compounds are extracted and purified by means of biochemistry methods and are amenable for innovative drug delivery systems as well. CK2 kinase inhibitors have been proven suitable for combined therapies with other investigational antiglioma agents and treatment modalities. However a greater share of efforts should be undertaken towards inhibiting functions relatively specific for glial tumors including infiltrative growth and invasiveness or maintenance of glioma initiating cells. Many of these function appear to converge on mTOR and JAK/STAT pathways which are being meticulously studied in this respect. Protein kinase CK2 holds therapeutic promise especially when combined with other agents aimed at molecular signatures of gliomas.
{"title":"Inhibitors of CK2 Kinase for the Treatment of Gliomas and Other Brain Tumors","authors":"E. Pucko, Robert P. Ostrowski","doi":"10.32383/appdr/183629","DOIUrl":"https://doi.org/10.32383/appdr/183629","url":null,"abstract":"Protein kinase CK2 has become a target of experimental antiglioma therapies as laboratory data are almost uniformly favorable and the number of synthetized CK2 inhibitors is rapidly growing. The evidence of their use for other brain tumors is on the increase as well. Great expectations are entrusted in naturally occurring compounds capable of inhibiting CK2 kinase. These compounds are extracted and purified by means of biochemistry methods and are amenable for innovative drug delivery systems as well. CK2 kinase inhibitors have been proven suitable for combined therapies with other investigational antiglioma agents and treatment modalities. However a greater share of efforts should be undertaken towards inhibiting functions relatively specific for glial tumors including infiltrative growth and invasiveness or maintenance of glioma initiating cells. Many of these function appear to converge on mTOR and JAK/STAT pathways which are being meticulously studied in this respect. Protein kinase CK2 holds therapeutic promise especially when combined with other agents aimed at molecular signatures of gliomas.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140722977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qi Huang, Yingli Zhao, X J Fang, Jianjun Liu, Quan Xia, Chao Tan, Yao Peng, Jingjing Wu
Dear Editor, In our subsequent study after the receipt of the article, it was found that the P84Ms carrier had certain cytotoxicity. As can be seen from the Figure 1 and Figure 2, compared with the cells in the control group, after incubation with different prepare preparations, the single carrier group Micelles-Blank and Mixed Micelles-Blank could inhibit the growth of the cells. However, the cytotoxicity data in the paper did not set Micelles-Blank and Mixed Micelles-Blank groups, which was also an oversight of our design at that time. Hence it is hard to say whether the therapeutic effect of the preparation is due to the toxicity of the carrier or the therapeutic effect of the drug in this article Therefore, the statement in the article that the carrier is safe and effective may be wrong. So the article needs to be withdrawn, and we will further modify the carrier in the future to reduce its toxicity.
{"title":"Retraction: Development and optimization of TPGS/P84 mixed polymeric micelles: enhanced stability and anticancer effect of paclitaxel against tumor therapy","authors":"Qi Huang, Yingli Zhao, X J Fang, Jianjun Liu, Quan Xia, Chao Tan, Yao Peng, Jingjing Wu","doi":"10.32383/appdr/175521","DOIUrl":"https://doi.org/10.32383/appdr/175521","url":null,"abstract":"Dear Editor, In our subsequent study after the receipt of the article, it was found that the P84Ms carrier had certain cytotoxicity. As can be seen from the Figure 1 and Figure 2, compared with the cells in the control group, after incubation with different prepare preparations, the single carrier group Micelles-Blank and Mixed Micelles-Blank could inhibit the growth of the cells. However, the cytotoxicity data in the paper did not set Micelles-Blank and Mixed Micelles-Blank groups, which was also an oversight of our design at that time. Hence it is hard to say whether the therapeutic effect of the preparation is due to the toxicity of the carrier or the therapeutic effect of the drug in this article Therefore, the statement in the article that the carrier is safe and effective may be wrong. So the article needs to be withdrawn, and we will further modify the carrier in the future to reduce its toxicity.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"80 6","pages":"1043-1043"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"http://dx.doi.org/10.32383/appdr/175521","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147915233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This experiment used mice as the experimental subjects to study the alleviating effect of Lactobacillus pentosus CQZC01 (LPCQZC01) on antibiotic-induced diarrhea in mice. After adaptive feeding for seven days, Kunming (KM) mice were randomly divided into the following groups: positive control group, model group, normal group, high concentration group of LPCQZC01 (H-LPCQZC01, 1×109 CFU/mL), and low concentration group of LPCQZC01 (L-LPCQZC01, 1×108 CFU/mL). Except for the normal group, mice were orally administered with lincomycin hydrochloride (120 mg/day) for 7 consecutive days. Changes in body weight, food intake, water consumption, and fecal water content of mice were observed. A histological examination of mouse colon and small intestine sections was done to find out if Lactobacillus pentosus CQZC01 may help mice with antibiotic-induced diarrhea. The findings demonstrated that, in comparison to the model group, mice in the H-LPCQZC01 and L-LPCQZC01 groups had considerably lower blood levels of nterleukin-6 (IL-6), interleukin-17A (IL-17A), 5-hydroxytryptamine (5-HT), and malondialdehyde (MDA), and other variables. In comparison to the model group, the fecal water content in the H-LPCQZC01 and L-LPCQZC01 groups was considerably lower. The H-LPCQZC01 and L-LPCQZC01 groups consumed more food and liquids than the model group did. The H-LPCQZC01 and L-LPCQZC01 groups had more intact colon walls and more compact, regular, and organized intestinal villi. H-LPCQZC01 and L-LPCQZC01 groups had the lower CFTR, EGFR expression and stronger NHE1, NHE2 expression than model group. This study reveals that Lactobacillus pentosus CQZC01 may treat inflammatory lesions in the mouse intestines and successfully treat antibiotic-induced diarrhea in mice.
{"title":"Alleviating effect of Lactobacillus pentosus CQZC01 probiotic strain on antibiotic-induced diarrhea in mice","authors":"Yanqing Liu, Mengqin Cheng, Bihui Liu, Mengwei Wang, Jing Song, Xin Zhao, Ruokun Yi, X. Long, Huazhi Liu","doi":"10.32383/appdr/176426","DOIUrl":"https://doi.org/10.32383/appdr/176426","url":null,"abstract":"This experiment used mice as the experimental subjects to study the alleviating effect of Lactobacillus pentosus CQZC01 (LPCQZC01) on antibiotic-induced diarrhea in mice. After adaptive feeding for seven days, Kunming (KM) mice were randomly divided into the following groups: positive control group, model group, normal group, high concentration group of LPCQZC01 (H-LPCQZC01, 1×109 CFU/mL), and low concentration group of LPCQZC01 (L-LPCQZC01, 1×108 CFU/mL). Except for the normal group, mice were orally administered with lincomycin hydrochloride (120 mg/day) for 7 consecutive days. Changes in body weight, food intake, water consumption, and fecal water content of mice were observed. A histological examination of mouse colon and small intestine sections was done to find out if Lactobacillus pentosus CQZC01 may help mice with antibiotic-induced diarrhea. The findings demonstrated that, in comparison to the model group, mice in the H-LPCQZC01 and L-LPCQZC01 groups had considerably lower blood levels of nterleukin-6 (IL-6), interleukin-17A (IL-17A), 5-hydroxytryptamine (5-HT), and malondialdehyde (MDA), and other variables. In comparison to the model group, the fecal water content in the H-LPCQZC01 and L-LPCQZC01 groups was considerably lower. The H-LPCQZC01 and L-LPCQZC01 groups consumed more food and liquids than the model group did. The H-LPCQZC01 and L-LPCQZC01 groups had more intact colon walls and more compact, regular, and organized intestinal villi. H-LPCQZC01 and L-LPCQZC01 groups had the lower CFTR, EGFR expression and stronger NHE1, NHE2 expression than model group. This study reveals that Lactobacillus pentosus CQZC01 may treat inflammatory lesions in the mouse intestines and successfully treat antibiotic-induced diarrhea in mice.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"25 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139826652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This experiment used mice as the experimental subjects to study the alleviating effect of Lactobacillus pentosus CQZC01 (LPCQZC01) on antibiotic-induced diarrhea in mice. After adaptive feeding for seven days, Kunming (KM) mice were randomly divided into the following groups: positive control group, model group, normal group, high concentration group of LPCQZC01 (H-LPCQZC01, 1×109 CFU/mL), and low concentration group of LPCQZC01 (L-LPCQZC01, 1×108 CFU/mL). Except for the normal group, mice were orally administered with lincomycin hydrochloride (120 mg/day) for 7 consecutive days. Changes in body weight, food intake, water consumption, and fecal water content of mice were observed. A histological examination of mouse colon and small intestine sections was done to find out if Lactobacillus pentosus CQZC01 may help mice with antibiotic-induced diarrhea. The findings demonstrated that, in comparison to the model group, mice in the H-LPCQZC01 and L-LPCQZC01 groups had considerably lower blood levels of nterleukin-6 (IL-6), interleukin-17A (IL-17A), 5-hydroxytryptamine (5-HT), and malondialdehyde (MDA), and other variables. In comparison to the model group, the fecal water content in the H-LPCQZC01 and L-LPCQZC01 groups was considerably lower. The H-LPCQZC01 and L-LPCQZC01 groups consumed more food and liquids than the model group did. The H-LPCQZC01 and L-LPCQZC01 groups had more intact colon walls and more compact, regular, and organized intestinal villi. H-LPCQZC01 and L-LPCQZC01 groups had the lower CFTR, EGFR expression and stronger NHE1, NHE2 expression than model group. This study reveals that Lactobacillus pentosus CQZC01 may treat inflammatory lesions in the mouse intestines and successfully treat antibiotic-induced diarrhea in mice.
{"title":"Alleviating effect of Lactobacillus pentosus CQZC01 probiotic strain on antibiotic-induced diarrhea in mice","authors":"Yanqing Liu, Mengqin Cheng, Bihui Liu, Mengwei Wang, Jing Song, Xin Zhao, Ruokun Yi, X. Long, Huazhi Liu","doi":"10.32383/appdr/176426","DOIUrl":"https://doi.org/10.32383/appdr/176426","url":null,"abstract":"This experiment used mice as the experimental subjects to study the alleviating effect of Lactobacillus pentosus CQZC01 (LPCQZC01) on antibiotic-induced diarrhea in mice. After adaptive feeding for seven days, Kunming (KM) mice were randomly divided into the following groups: positive control group, model group, normal group, high concentration group of LPCQZC01 (H-LPCQZC01, 1×109 CFU/mL), and low concentration group of LPCQZC01 (L-LPCQZC01, 1×108 CFU/mL). Except for the normal group, mice were orally administered with lincomycin hydrochloride (120 mg/day) for 7 consecutive days. Changes in body weight, food intake, water consumption, and fecal water content of mice were observed. A histological examination of mouse colon and small intestine sections was done to find out if Lactobacillus pentosus CQZC01 may help mice with antibiotic-induced diarrhea. The findings demonstrated that, in comparison to the model group, mice in the H-LPCQZC01 and L-LPCQZC01 groups had considerably lower blood levels of nterleukin-6 (IL-6), interleukin-17A (IL-17A), 5-hydroxytryptamine (5-HT), and malondialdehyde (MDA), and other variables. In comparison to the model group, the fecal water content in the H-LPCQZC01 and L-LPCQZC01 groups was considerably lower. The H-LPCQZC01 and L-LPCQZC01 groups consumed more food and liquids than the model group did. The H-LPCQZC01 and L-LPCQZC01 groups had more intact colon walls and more compact, regular, and organized intestinal villi. H-LPCQZC01 and L-LPCQZC01 groups had the lower CFTR, EGFR expression and stronger NHE1, NHE2 expression than model group. This study reveals that Lactobacillus pentosus CQZC01 may treat inflammatory lesions in the mouse intestines and successfully treat antibiotic-induced diarrhea in mice.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"22 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139886370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Czajkowska-Kośnik, Zofia Helena Bagińska, K. Winnicka
Dry skin is the common problem affecting people which triggers many unpleasant symptoms such as roughness, peeling, burning, itching and greater sensitivity to injury and external conditions. One method to assess the water loss of skin is transepidermal water loss (TEWL) measurement. Various active substances, for instance allantoin and D-panthenol, can be used to overcome the symptoms of the dry skin. In this study, emulsions containing allantoin and D-panthenol as moisturizing agents and various oils (liquid paraffin, Cannabis sativa, Baobab and Coconut oil) were developed. The prepared emulsions were characterized by: visual and microscopic appearance and pH values. Stability analysis was conducted by centrifuge test and sensory test using sensory sensation was evaluated. Rheological experiments were performed using a rheometer, while mechanical and adhesion tests by texture analyzer. TEWL values were measured using a tewameter, after application of the emulsions to the responders skin. TEWL study noticed that regular permanent use of moisturizing emulsions with allantoin and D-panthenol limited the water loss. In conclusion, it can be stated that emulsions containing allantoin and D-panthenol as active agents and Coconut oil as oily ingredient are attractive formulations with moisturizing effect and good application features.
{"title":"Emulsions containing allantoin and D-panthenol as attractive moisturizing agents","authors":"A. Czajkowska-Kośnik, Zofia Helena Bagińska, K. Winnicka","doi":"10.32383/appdr/174461","DOIUrl":"https://doi.org/10.32383/appdr/174461","url":null,"abstract":"Dry skin is the common problem affecting people which triggers many unpleasant symptoms such as roughness, peeling, burning, itching and greater sensitivity to injury and external conditions. One method to assess the water loss of skin is transepidermal water loss (TEWL) measurement. Various active substances, for instance allantoin and D-panthenol, can be used to overcome the symptoms of the dry skin. In this study, emulsions containing allantoin and D-panthenol as moisturizing agents and various oils (liquid paraffin, Cannabis sativa, Baobab and Coconut oil) were developed. The prepared emulsions were characterized by: visual and microscopic appearance and pH values. Stability analysis was conducted by centrifuge test and sensory test using sensory sensation was evaluated. Rheological experiments were performed using a rheometer, while mechanical and adhesion tests by texture analyzer. TEWL values were measured using a tewameter, after application of the emulsions to the responders skin. TEWL study noticed that regular permanent use of moisturizing emulsions with allantoin and D-panthenol limited the water loss. In conclusion, it can be stated that emulsions containing allantoin and D-panthenol as active agents and Coconut oil as oily ingredient are attractive formulations with moisturizing effect and good application features.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":"48 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139687456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：